New combo therapy aims to improve diabetes control
NCT ID NCT07580638
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study looks at whether adding the drug Chiglitazar to standard SGLT-2 inhibitor therapy helps adults with type 2 diabetes achieve better blood sugar control. About 3,550 participants will be followed during their regular care to track changes in blood sugar, heart, kidney, and liver health. The goal is to see if this combination is safe and effective in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.